TCL Archive Stephen Gruber Named Director at USC Norris; TGen and Cedars-Sinai to Coordinate Phase I Trials. October 21, 2011
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive NCI Planning To Switch Drug Development Emphasis From Compound To Human Cancer Oriented Strategy October 26, 1984
